Details for Patent: 10,071,066

Which drugs does patent 10,071,066 protect, and when does it expire?

Patent 10,071,066 protects ORSERDU and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 10,071,066

Title:	Method of treating cancer using selective estrogen receptor modulators
Abstract:	Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Inventor(s):	Wardell Suzanne E., Nelson Erik R., McDonnell Donald P.
Assignee:	Duke University
Application Number:	US15214187
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,071,066

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-001	Jan 27, 2023		RX	Yes	No						TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY
Stemline Therap	ORSERDU	elacestrant dihydrochloride	TABLET;ORAL	217639-002	Jan 27, 2023		RX	Yes	Yes						TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY

International Family Members for US Patent 10,071,066

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2943611
Denmark	3122426
European Patent Office	3122426		CA 2024 00007	Denmark